<DOC>
	<DOCNO>NCT00864162</DOCNO>
	<brief_summary>To compare rate absorption oral bioavailability test formulation Ramipril10 mg Capsules manufacture Purepac Pharmaceutical Company equivalent oral dose commercially available reference product Atlace® manufacture Monarch Pharmaceuticals Inc. administrate healthy subject 10-hour overnight fast follow high-calorie , high-fat breakfast meal .</brief_summary>
	<brief_title>A Relative Bioavailability Study Ramipril 10 mg Capsules Under Fed Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : A single-dose , open-label , randomize , two-period crossover study Official Title : A Single-Dose , 2-Period , 2-Treatment , 2-Way Crossover Bioequivalence Study Ramipril10 mg Capsules Under Fed Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Subject must male nonpregnant , nonbreastfeeding female . Subject must 18 55 year age inclusive . Subject 's body weight within ±15 % ideal body weight height estimate frame base Metropolitan Life Insurance Company Table . Female subject childbearing potential surgically sterile least two year postmenopausal must agree utilize one follow form contraception , sexually active male partner , screen completion study . Approved forms contraception abstinence , hormonal ( oral , implant , transdermal injection ) , double barrier ( condom diaphragm spermicide ) , IUD , vasectomize partner ( 6 month minimum ) . Subject must voluntarily consent participate study provide write informed consent prior completion studyspecific procedure . Subject willing able remain research center entire duration confinement period return research center outpatient visit . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic psychiatric disease condition , opinion Investigator would jeopardize safety subject validity study result . Has clinically significant abnormal find physical exam , medical history clinical laboratory result screen . History presence allergic adverse response study drug relate drug . Has significantly abnormal diet four week precede first dose study medication . Has donate blood plasma within 30 day prior first dose study medication . Has participate another clinical trial within 30 day prior first dose study medication . Has use overthecounter ( OTC ) medication include vitamin , within 7 day prior first dose study medication . Has use prescription medication , except hormonal contraceptive hormonal replacement therapy , within 7 day prior first dose study medication . Has treat know enzyme alter drug barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication . Has smoke use tobacco product within 60 day prior first dose study medication . Has history substance abuse ( include alcohol ) past 5 year Is female positive pregnancy test . Positive urine screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , cannabinoids , opiate ) . Has positive test , treat hepatitis B , hepatitis C HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Ramipril</keyword>
	<keyword>Healthy subject</keyword>
</DOC>